Pulmonary Arterial Hypertension

To stress the importance of considering pulmonary complications in sickle cell disease (SCD), researchers compiled an overview on the state of research and available treatment options for patients with SCD associated with pulmonary hypertension.

A Biologics License Application has been submitted to the FDA review for sotatercept in the treatment of pulmonary arterial hypertension.

In a recent review, researchers overviewed the challenging aspects of treating pulmonary arterial hypertension (PAH), highlight the genetic and etiological variability, and advocate for research to expand personalized medicine.

Data from the SPHERE registry revealed racial and ethnic discrepancies in disease severity, comorbidities, and outcomes experienced by patients with pulmonary arterial hypertension (PAH) receiving selexipag.

At ERS International Congress 2023, new data related to use of sotatercept offered providers additional insight into the effects of the agent in people with pulmonary arterial hypertension (PAH).

Researchers used real-world data to further validate the use of selexipag in the management of pulmonary arterial hypertension (PAH).

This new data represents the first real-world, US-based data on this drug, demonstrating the efficacy and the safety indications of these clinical trials.

Atrioventricular interval modulation (AVIM) therapy for hypertension may help address this common comorbidity among patients with pacemakers.

Most people don’t know they have hypertension, and a new recommendation advises that pregnant women should be screened for blood pressure disorders at every appointment; patients in primary care face long wait times, which may be due to physician incentives under value-based payments; a lawsuit in New Jersey targets the residency requirement to allow aid in dying for those out of state.

An observational study confirms that the COVID-19 pandemic significantly disrupted care for patients with pulmonary arterial hypertension (PAH).

This retrospective study found associations between inferior nutritional index scores, malnutrition, and prognoses in patients with pulmonary arterial hypertension (PAH).

A cross-sectional study suggests that mild cognitive impairment is associated with pulmonary arterial hypertension (PAH).

Investigators also did not find a threshold below which this association was lost.

About 17 million middle-class Americans have unpaid medical bills; more than 1 in 5 patients hospitalized with COVID-19 developed high blood pressure; work requirements for Supplemental Nutrition Assistance Program (SNAP) benefits to begin in September.

Study authors investigated the effect of physical activity as a modifiable risk factor among individuals living with high-risk hypertension in this subanalysis of data from the Systolic Blood Pressure Intervention Trial (SPRINT).

Called the TRIO comprehensive, integrated patient data repository (TRIO CIPDR), the unique registry combines clinical data from electronic health records with pharmacy data, including PAH-specific drugs prescribed, as well as the dates prescribed, administered, and refilled.

When used in conjunction with other risk factors, the 6 distinct blood pressure patterns were able to accurately predict and stratify risk of hypertensive disorders of pregnancy regardless of race or ethnicity.

This retrospective study shows that among nearly 160,000 patients with pulmonary hypertension (PH), those who also had gastroesophageal reflux disease (GERD) had lower rates of morbidity and mortality.

The cross-sectional study found that higher childhood neighborhood area deprivation index (ADI), obesity, age, sex, and length of Medicaid benefit coverage are all associated with a primary hypertension diagnosis among youth residing in Delaware.

The model has potential to assist integrated delivery network health care providers through early identification of patients with pulmonary arterial hypertension (PAH), a rare but fast-progressing condition.

These patients experienced overall improvements in objective health outcomes during the crisis compared with before the health emergency.

Both genera and regional anesthesia can be safely used in patients with pulmonary arterial hypertension (PAH).

Results are based on a series of surveys completed by 17 experts.

The pilot program for pulmonary arterial hypertension (PAH) was carried out at a single center in the Netherlands.

Patients who have pulmonary arterial hypertension (PAH) often do not feel better after treatment, even if they meet clinical endpoints for improvement.

Pulmonary arterial hypertension (PAH) is the only major diagnostic indication for transplantation that is not a parenchymal pulmonary process.

If approved by the FDA, sotatercept would be the first therapy that acts directly against the cause of the disease.

Researchers set out to examine the effects of sodium nitroprusside on the thromboxane-mediated contraction and nitric oxide (NO)-independent relaxation pathways and on reactive oxygen species accumulation in pulmonary artery smooth muscle cells.

A Danish study of nationwide registries estimated a 39% greater risk of high refractive error among children of mothers with hypertensive disorder of pregnancy (HDP), a complication that affects 5% to 10% of pregnancies.

These insights represent the first characterization of risk factors for respiratory failure–related hospitalization among patients with sarcoidosis‐associated pulmonary hypertension (SAPH).